Molecular and Cellular Pathology

British Journal of Cancer (2003) 88, 1095–1100. doi:10.1038/sj.bjc.6600870 www.bjcancer.com
Published online 1 April 2003

Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites

G J J Van Doornum1,2,4, C M Korse2, J C G M Buning-Kager2, J M G Bonfrer2, S Horenblas2, B G Taal2 and J Dillner3,5

  1. 1Slotervaart Hospital, Amsterdam, The Netherlands
  2. 2Antoni van Leeuwenhoek Hospital and Netherlands Cancer Institute, Amsterdam, The Netherlands
  3. 3Microbiology and Tumor Biology Centre, Karolinska Institute, Stockholm, Sweden

Correspondence: Dr GJJ Van Doornum, Erasmus MC Rotterdam, Department of Virology, L355, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. E-mail: vandoornum@viro.azr.nl

4Current addresses: Erasmus MC, Rotterdam, The Netherlands

5Department of Medical Microbiology, MAS University Hospital, Lund, Sweden

Received 19 August 2002; Revised 7 January 2003; Accepted 4 February 2003.

Top

Abstract

A retrospective seroepidemiologic study was performed to examine the association between human papillomaviruses (HPV) 16 infection and carcinomas of the oropharynx, the oesophagus, penis and vagina. Sera were selected from the serum bank from the Antoni van Leeuwenhoek Hospital (Netherlands Cancer Institute) and the Slotervaart Hospital in Amsterdam, the Netherlands. Presence of HPV 16 specific antibody was assessed using HPV 16 L1 capsids. Sera positive for HPV 16 capsid antibody were further tested for antibody against HPV 16 E7 peptides. Prevalence of antibody against HPV 16 L1 capsids among both the negative control group without cancer and the negative control group with gastric cancer was 18%, while seroprevalence among the control group of patients with HPV-associated cervical squamous cell carcinoma was 47% (P<0.001). Among the patients with penile squamous cell carcinoma seroprevalence was 38% (P<0.001), among patients with oropharyngeal carcinoma 33% (P=0.04) and among patients with oesophageal squamous cell carcinoma 14% (P=0.7). The serological evidence for association between HPV 16 infection and both oropharyngeal carcinoma and penile carcinoma was established. The conclusion that no association was found between the presence of antibody against HPV 16 L1 capsids and oesophageal squamous cell carcinoma was in accordance with results of other studies carried out in the Netherlands using HPV DNA technology. In the subjects with HPV 16 L1 capsid antibody, no association was found between the antibody against HPV 16 E7 and clinical outcome.

Keywords:

HPV 16 serology, oropharyngeal carcinoma, oesophageal carcinoma, cervical cancer, vaginal and vulvar cancer, penile carcinoma